UNICEF begins shipping syringes for the global rollout of COVID-19 vaccines under COVAX
– UNICEF has sent 100,000 syringes and 1,000 safety boxes for COVID-19 vaccinations to the Maldives by air freight from UNICEF’s humanitarian warehouse in Dubai—part of the first wave of COVID-19-related syringe shipments to begin rolling out in the coming days. Others in the first wave of shipments include Côte d'Ivoire and São Tomé and Príncipe. The 0.5 ml syringes and safety boxes are expected to arrive in Malé, Maldives on Tuesday. Over the next few weeks, UNICEF will ship more than 14.5 million 0.5 ml and 0.3 ml auto-disable syringes to more than 30 countries. While the 0.5 ml syringes are meant for use with the Serum Institute of India/AstraZeneca vaccine, the 0.3 ml ones are to be used with the Pfizer-BioNTech vaccine. “In this global fight against the COVID-19 pandemic, syringes are as vital as the vaccine itself,” said UNICEF Executive Director Henrietta Fore. “It is critical to have adequate supplies of syringes already in place in every country before the vaccine arrives so that the vaccine can be administered safely. This would allow immunization to start immediately and help turn the tide on this terrible virus.” The countries that will receive syringes in this initial tranche are from those included in the COVAX indicative distribution and that have put in requests to UNICEF to supply syringes. These shipments will support the country rollout of COVID-19 vaccines, and is part of work by the COVAX Facility to provide vaccines to all participating countries. The 0.5 ml syringes are being dispatched from UNICEF’s humanitarian warehouse in Dubai, while the 0.3 ml & 2 ml syringes will be transported directly from a manufacturer in Spain. The consignments will also include safety boxes for the safe disposal of syringes. Both syringes are of the auto-disable type, which means they cannot be used again after a single dose of vaccine has been administered. This reduces the risk of infection from blood-borne diseases as a result of syringe re-use. In all, UNICEF will be supplying up to 1 billion syringes and 10 million safety boxes to countries in 2021 to ensure they are ready for COVID-19 vaccinations. In order to meet the demand for these vital supplies, UNICEF created a stockpile of almost half a billion syringes in its warehouses in Copenhagen and Dubai in preparation for the broader rollout of COVID-19 vaccines in 82 low- and lower middle-income countries. UNICEF has been working with airlines, logistics operators and freight forwarders to ensure the syringes are treated as priority freight, whether they are being shipped direct from a manufacturer or from UNICEF warehouses to the destination country’s port of entry. Although the first deliveries will be transported by air, most of the syringes and safety boxes will be transported by sea due to the large amount of space they take up as cargo. UNICEF is aiming to make 2 billion COVID-19 doses available for delivery in 2021. Even before COVID-19, UNICEF was already the largest single vaccine buyer in the world, procuring over 2 billion vaccines annually in order to reach almost half of the world’s children under 5. In addition, the agency procures and supplies around 600-800 million syringes for regular immunization programmes annually. COVAX is a global collaboration co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, and includes UNICEF, which leads on procurement and delivery, as well as getting countries ready to receive vaccines. ##### Двое мужчин на складе с коробками UNICEF/UN0419486/Pableo
UNICEF to lead procurement and supply of COVID-19 vaccines in world’s largest and fastest ever operation of its kind
– UNICEF is leading efforts to procure and supply COVID-19 vaccines in what could possibly be the world’s largest and fastest ever procurement and supply of vaccines, as part of the global vaccine plan of the COVID-19 Vaccine Global Access Facility (COVAX Facility) led by Gavi, the Vaccine Alliance. With several vaccine candidates showing promise, UNICEF, in collaboration with the PAHO Revolving Fund , will lead efforts to procure and supply doses of COVID-19 vaccines on behalf of the COVAX Facility for 92 low- and lower middle-income countries whose vaccine purchases will be supported by the mechanism through the Gavi COVAX AMC as well as a buffer stockpile for humanitarian emergencies. In addition, UNICEF will also serve as procurement coordinator to support procurement by 80 higher-income economies , which have expressed their intent to participate in the COVAX Facility and would finance the vaccines from their own public finance budgets. UNICEF will undertake these efforts in close collaboration with WHO, Gavi, CEPI, PAHO, World Bank, the Bill and Melinda Gates Foundation and other partners. The COVAX Facility is open to all countries to ensure that no country is left without access to a future COVID-19 vaccine. “This is an all-hands on deck partnership between governments, manufacturers and multilateral partners to continue the high-stakes fight against the COVID-19 pandemic,” said Henrietta Fore, UNICEF Executive Director. “In our collective pursuit of a vaccine, UNICEF is leveraging its unique strengths in vaccine supply to make sure that all countries have safe, fast and equitable access to the initial doses when they are available.” UNICEF is the largest single vaccine buyer in the world, procuring more than 2 billion doses of vaccines annually for routine immunization and outbreak response on behalf of nearly 100 countries. It is the main procurement partner of Gavi, the Vaccine Alliance, which over the last 20 years has reached more than 760 million children with life-saving vaccines, preventing more than 13 million deaths. UNICEF will use its market shaping and procurement expertise to coordinate the procurement and supply of COVID-19 vaccines for the COVAX Facility. This could potentially double the agency’s overall vaccine procurement throughput volume in 2021 alone. In response to an expression of interest that UNICEF issued in June on behalf of the COVAX Facility, 28 manufacturers with production facilities in 10 countries shared their annual production plans for COVID-19 vaccines through 2023. According to the timelines the manufacturers indicated, the span from development to production could be one of the fastest scientific and manufacturing leaps in history. A UNICEF market assessment , developed by compiling information submitted by vaccine manufacturers along with publicly available data, revealed that manufacturers are willing to collectively produce unprecedented quantities of vaccines over the coming 1-2 years. However, manufacturers signaled that investments to support such large-scale production of doses would be highly dependent on, among other things, whether clinical trials are successful, advance purchase agreements are put in place, funding is confirmed, and regulatory and registration pathways are streamlined. This assessment also illustrates, among other things, manufacturers’ responsiveness to the COVAX Facility’s design and objectives—a key pillar of the ACT-Accelerator initiative , which is a new, groundbreaking global collaboration to accelerate the development and equitable distribution of vaccines, diagnostics and therapeutics to address the COVID-19 pandemic across countries of all income levels. A key next step will be ensuring self-financing economies sign up for the COVAX Facility by 18 September, which will allow COVAX to support early, at-risk investments in increasing manufacturing capacity on a broad scale, through advance purchase agreements. Currently under development by WHO, the COVAX allocation framework will guide how and where UNICEF, PAHO and other procurers working on behalf of participating countries supply COVID-19 vaccines that are secured by the Facility. Initial dose allocations are expected to be scaled to enable countries to vaccinate health and social workers, followed by subsequent tranches of vaccine doses that would enable participating countries to vaccinate populations at higher risk of critical COVID-19 disease. “UNICEF has been critical partner in the Alliance’s success over the last two decades – helping us reach more than half the world’s population with life-saving vaccines,” said Dr. Seth Berkley, CEO of Gavi. “This expertise and experience will be important in ensuring that COVAX – as a global effort to procure and deliver safe and effective COVID-19 vaccines, on an accelerated timeframe, and at an unprecedented scale – can protect the most at-risk, wherever they may be in the world. Together we can work to end the acute stage of this pandemic, including its devastating impact on individuals, communities, and economies.” UNICEF, Gavi, WHO, and PAHO have started critical preparatory work for country vaccine readiness in collaboration with partners and national governments including: Working with device manufacturers to plan availability of safe injection equipment and cold chain requirements for the vaccine; Developing guidance with WHO and trainings to support vaccination policies and appropriate handling, store and distribution of the vaccines; Working with manufacturers on freight and logistics solutions to get vaccine doses to countries as quickly and safely as possible once they are allocated; Supporting countries in planning for vaccine delivery, including targeting those most at risk and transport and storage at point of service delivery; Ramping up efforts with civil society and other local partners to ensure that people are well-informed about the COVID-19 vaccination process and putting measures in place to enhance trust and tackle misinformation about COVID-19 vaccines. UNICEF Supply UNICEF/UNI325740/Montico
What you need to know about COVID-19 vaccines
Vaccines work by mimicking an infectious agent – viruses, bacteria or other microorganisms that can cause a disease. This ‘teaches’ our immune system to rapidly and effectively respond against it. Traditionally, vaccines have done this by introducing a weakened form of an infectious agent that allows our immune system to build a memory of it. This way, our immune system can quickly recognize and fight it before it makes us ill. That’s how some of the COVID-19 vaccines have been designed. Other COVID-19 vaccines have been developed using new approaches, which are called messenger RNA, or mRNA, vaccines. Instead of introducing antigens (a substance that causes your immune system to produce antibodies), mRNA vaccines give our body the genetic code it needs to allow our immune system to produce the antigen itself. mRNA vaccine technology has been studied for several decades. They contain no live virus and do not interfere with human DNA. For more information on how vaccines work, please visit WHO .
Leading airlines commit to helping UNICEF in its historic mission of transporting COVID-19 vaccines around the world
UNICEF is today launching the Humanitarian Airfreight Initiative. Under this landmark initiative, over 10 leading airlines are signing agreements with UNICEF to support the prioritization of delivery of COVID-19 vaccines, essential medicines, medical devices and other critical supplies to respond to the pandemic. The Initiative will also act as a global logistics preparedness mechanism for other humanitarian and health crises over the longer term. “Delivery of these life-saving vaccines is a monumental and complex undertaking, considering the sheer volumes that need to be transported, the cold chain requirements, the number of expected deliveries and the diversity of routes” said Etleva Kadilli, Director of UNICEF Supply Division. “We are grateful to these airlines for joining forces with the UNICEF Humanitarian Airfreight Initiative to support the roll-out of COVID-19 vaccines.” The UNICEF Humanitarian Airfreight Initiative brings together the airlines covering routes to over 100 countries, in support of the COVAX Facility – the global effort aimed at equitable access to COVID-19 vaccines. Based on the COVAX Facility’s indicative distribution and first round allocation plan, 145 countries will receive doses to immunize around three per cent of their population, on average, starting in the first half of 2021, subject to all requirements being met and final allocation plans. In addition to prioritizing shipments of these life-saving supplies, the airlines will take measures such as temperature control and security, while also adding freight capacity to routes where needed. Their commitments are critical to the timely and secure delivery of vaccines and critical supplies. Safe, timely and efficient transportation of life-saving supplies is critical to supporting access to essential services for children and families. COVAX deliveries and the subsequent vaccination of frontline workers will support health and social care systems to safely resume these critical services. Man next to a plane UNICEF/UNI319459/Rocio Ortega